Airway Therapeutics is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases. The company is advancing the novel recombinant human protein rhSP-D - an engineered version of the endogenous protein hSP-D - that reduces inflammation and infection while modulating the immune response.